Andrew Hopkins, Exscientia CEO
September 13, 2021 07:19 AM EDT
Financing
AI

Ex­sci­en­tia tees up an IPO for its AI drug dis­cov­ery plat­form, like­ly not will­ing to set­tle for just $100M

Max Gelman

Senior Editor

The biotech IPO mar­ket awoke from its sum­mer hi­ber­na­tion on Fri­day morn­ing with a small AD­HD drug de­vel­op­er seek­ing a mod­est raise, but late …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times